TB-500 speeds soft tissue recovery in humans.
TB-500Verdict: Overhyped. Last reviewed Jul 1, 2026. Risk signal: High.
Peptide evidence profile
TB-500 is usually promoted around soft-tissue recovery and training setbacks. We separate those claims by exact outcome before grading the supporting evidence.
Peptide Fact Checks reviews narrow claims one at a time. A claim only becomes public when it has a grade, verdict, source list, and last-reviewed date.
Verdict: Overhyped. Last reviewed Jul 1, 2026. Risk signal: High.
Claims around repair, recovery speed, and injectable use can cross into high-risk promotional territory and require human review.
Treat broad recovery promises cautiously unless the claim points to relevant human evidence and clear regulatory context.